Cell & Gene Therapy Manufacturing Services Market Segmentation:
Mode (Contract manufacturing, In-house manufacturing)
The contract manufacturing segment is poised to hold over 87.8% cell & gene therapy manufacturing services market share by the end of 2035. Companies’ rising outsourcing of manufacturing activities to streamline production procedures and fast-track time-to-market for their therapies is majorly driving the segment’s growth. The dynamic regulatory landscape, in addition to the requirement for flexibility in manufacturing capacity, is driving the growth further. In January 2024, Israeli cell technology company Pluri announced the expansion of the contract development and manufacturing division, PluriCDMO. The company intends to share its knowledge base, technology, and facilities to develop stem cells, induced pluripotent stem cells, exosomes, and Immunotherapeutics, with other businesses.
Type (Cell therapy, Gene therapy)
Based on type, gene therapy is projected to expand at a considerable CAGR during the forecast period in the cell & gene therapy manufacturing services market. A wide range of products are currently up for clinical trials, and manufacturing process improvement has become a significant need in the market. As per an article on gene therapy by Wiley, over 3,900 gene therapy trials were undertaken in 46 countries as per the March 2023 update. Furthermore, prominent companies are increasingly focusing on manufacturing and commercialization owing to rising funding and the clinical success of more products. Companies are undertaking several initiatives to enhance their presence in the manufacturing market.
Our in-depth analysis of the market includes the following segments:
|
Type |
|
|
Mode |
|
|
Indication |
|
|
End user |
|
